Molecular markers in well-differentiated thyroid cancer

D'Cruz, Anil; Vaish, Richa; Vaidya, Abhishek; Nixon, Iain J.; Williams, Michelle D.; Poorten, Vincent Vander; López, Fernando; Angelos, Peter; Shaha, Ashok R.; Khafif, Avi; Skálová, Alena; Rinaldo, Alessandra; Hunt, Jennifer L.; Ferlito, Alfio

doi:10.1007/s00405-018-4944-1

Cited by 36 publications

(33 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There has been a worldwide thyroid epidemic with 470,000 women and 90,000 men being diagnosed during the last two decades. Though the disease-specific mortality of thyroid cancer is low, unwarranted or inadequate surgery is associated with increased morbidity making proper management important ( D’Cruz et al, 2018 ). The promotion of Xn on I - uptake of FRTL-5 thyrocytes suggested that Xn might be an interesting candidate for increasing the sensitivity of radiotherapy on thyroid cancer ( Radovic et al, 2005 ).…”

Section: Head and Neck Cancersmentioning

confidence: 99%

Anticancer Activity and Mechanism of Xanthohumol: A Prenylated Flavonoid From Hops (Humulus lupulus L.)

et al. 2018

View full text Add to dashboard Cite

It has been observed that many phytochemicals, frequently present in foods or beverages, show potent chemopreventive or therapeutic properties that selectively affect cancer cells. Numerous studies have demonstrated the anticancer activity of xanthohumol (Xn), a prenylated flavonoid isolated from hops (Humulus lupulus L.), with a concentration up to 0.96 mg/L in beer. This review aims to summarize the existing studies focusing on the anticancer activity of Xn and its effects on key signaling molecules. Furthermore, the limitations of current studies and challenges for the clinical use of Xn are discussed.

show abstract

Section: Head and Neck Cancersmentioning

confidence: 99%

Anticancer Activity and Mechanism of Xanthohumol: A Prenylated Flavonoid From Hops (Humulus lupulus L.)

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In addition, 10%‐15% of PTC patients are still prone to relapse and distant metastasis, leading to a poor prognosis . Many studies have identified that genetic mutations and environmental factors are important in thyroid carcinogenesis, but many of the molecular mechanisms underlying TC pathogenesis remain unknown . Therefore, understanding the potential molecular mechanism underlying the oncogenesis and progression of TC is urgently needed.…”

Section: Introductionmentioning

confidence: 99%

Long noncoding RNA RP11‐547D24.1 regulates proliferation and migration in papillary thyroid carcinoma: Identification and validation of a novel long noncoding RNA through integrated analysis of TCGA database

et al. 2019

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) are known to be key regulators of numerous biological processes, and substantial evidence supports that abnormal lncRNA expression plays a significant role in tumorigenesis and tumor progression. However, the mechanism by which lncRNAs function in thyroid carcinoma are still unclear. To investigate the role of lncRNAs in the tumorigenesis of papillary thyroid carcinoma (PTC), we analyzed lncRNA data in The Cancer Genome Atlas RNA‐Seq database. A comparison of lncRNAs in cancerous thyroid tissues and normal tissues revealed hundreds of differentially expressed lncRNAs. Of 7589 lncRNAs identified in 561 thyroid cancer cases (503 cancerous tissues and 58 normal tissues), the expression levels of 144 were found to be aberrant (|log2 fold change| >2 and adjusted P < 0.05). The top 10 lncRNAs with the most significant differences were LINC01977, RP11‐363E7.4, RP3‐483K16.4, RP11‐547D24.1, RUNDC3A‐AS1, AC093609.1, CTD‐2008L17.2, HAGLROS, UNC5B‐AS1, and LINC01354. In addition, CTD‐2008L17.2, HAGLROS, AC093609.1, UNC5B‐AS1, and RUNDC3A‐AS1 were shown to play vital roles in determining the histological cancer type. Furthermore, RP11‐547D24.1 and UNC5B‐AS1 could distinguish patients with different stages of PTC. The lncRNA RP11‐547D24.1 was validated by loss‐of‐function assays, revealing that downregulation of this lncRNA regulates thyroid tumor cell proliferation and apoptosis, invasion, and migration. This study demonstrates the potential for using lncRNAs to interpret the pathogenesis and development of PTC.

show abstract

“…Abnormal DNA methylation, including a decrease in the overall methylation level of the genome, was accompanied by hypermethylation in some gene promoter regions. The hypermethylation of tumor suppressor gene promoter can reduce its expression, while the hypomethylation of tumor suppressor gene promoter can increase its expression, leading to tumorigenesis [5][6][7][8]. The following will describe the state of aberrant DNA methylation in different thyroid cancers.…”

Section: Introductionmentioning

confidence: 99%

Research Progress of DNA Methylation in Thyroid Cancer

Zhu¹,

Xie²

2020

DNA Methylation Mechanism

View full text Add to dashboard Cite

We have summarized increasing data from all kinds of experiment results of papers in recent years, which are associated with tumor suppressor genes, oncogenes, and thyroid-specific genes and attempt to elucidate the importance of epigenetic modifications and the mechanisms of aberrant DNA methylation in thyroid cancer in this review. The results showed that current articles have revealed the importance of epigenetic modifications and the different types of mechanisms in thyroid cancer. The mechanisms of DNA methylation related to thyroid cancer demonstrate that acquired epigenetic abnormalities together with genetic changes play an important role in alteration of gene expression patterns. Aberrant DNA methylation has been well known in the CpG regions. Among the genes identified, we have shown the status of DNA promoter methylation in papillary, follicular, medullary, and anaplastic thyroid cancer. It suggested that thyroid cancer subtypes present differential promoter methylation signatures, which will encourage potential thyroid cancer detection in its early stages, assessment of prognosis, and targeted cancer treatment.

show abstract

Molecular markers in well-differentiated thyroid cancer

Abstract: The prevalence of these mutations in thyroid nodule is high and it is a continuously evolving field. Clinicians should stay informed as recommendation on the use of these markers is expected to evolve.

Cited by 36 publications

References 85 publications

Anticancer Activity and Mechanism of Xanthohumol: A Prenylated Flavonoid From Hops (Humulus lupulus L.)

Anticancer Activity and Mechanism of Xanthohumol: A Prenylated Flavonoid From Hops (Humulus lupulus L.)

Long noncoding RNA RP11‐547D24.1 regulates proliferation and migration in papillary thyroid carcinoma: Identification and validation of a novel long noncoding RNA through integrated analysis of TCGA database

Research Progress of DNA Methylation in Thyroid Cancer

Contact Info

Product

Resources

About